Diabetes is seen as a “complicated disease” by clinicians, and its management is also perceived as complicated by patients. Despite management guidelines, approximately 63% of patients with diabetes are not at HbA1c goal (<7.0%) per the National Committee for Quality Assurance (NCQA). Patients with T2DM often present with comorbidities, which can further complicate antihyperglycemic treatment for both patients and clinicians. For example, despite control of standard risk factors, cardiovascular disease (CVD) remains the leading cause of death in patients with T2DM. Renal dysfunction also occurs frequently in these patients, and due to gaps in screening, it often goes undiagnosed until patients have later stage chronic kidney disease (CKD), which further increases the risk of CVD in patients with T2DM.
Updates to the Guidelines on Diabetes Management is designed to enhance clinician knowledge of the efficacy/safety profiles of available antihyperglycemic agents and explore the evidence from clinical trials and guidelines to appropriately individualize the management of patients with T2DM. The initiative will also help clinicians optimize the monitoring and treatment of associated comorbidities, while recognizing the importance of patient engagement in developing an effective diabetes care plan.